DNA methylation profiling reveals novel rhabdomyosarcoma subsets with distinct histologic, genetic and clinical properties

Cancer is often thought of as a single disease that strikes a specific organ, but in reality, it is a collection of many different diseases that happen to share a name. Within the family of childhood cancers, there is a group of tumors called rhabdomyosarcoma. These tumors arise from cells that are meant to become skeletal muscle, yet they fail to mature and instead grow out of control. For decades, doctors have sorted these tumors into two main buckets based on how they look under a microscope: one type resembles developing muscle in an embryo, and the other looks like a more structured, adult-like muscle. This visual sorting has guided treatment for years, but it has not always predicted how a child will do. Some children with the same-looking tumors respond very differently to therapy, suggesting that the visual appearance hides deeper biological differences. Scientists have long suspected that the instructions inside the cells, specifically how genes are turned on or off without changing the DNA code itself, might hold the key to understanding these differences.

A team of researchers recently set out to look past the surface appearance of these tumors and instead examine their chemical fingerprints. They focused on a process called DNA methylation, which acts like a set of sticky notes placed on the genetic code. These notes tell the cell which genes to use and which to ignore, effectively defining what kind of cell it is. By mapping these patterns across hundreds of tumor samples, the researchers discovered that the old two-bucket system was too simple. Their analysis revealed that rhabdomyosarcoma is actually a family of at least seven distinct subtypes, each with its own unique genetic makeup, history, and likely outcome. This finding suggests that the current way of diagnosing these tumors misses critical details that could change how doctors treat children in the future.

The study began with a massive collection of tumor samples, totaling 395 cases from two large groups of patients. The researchers used a high-tech scanner to read the methylation patterns across the entire genome of each tumor. When they arranged these patterns side by side, the tumors naturally sorted themselves into clusters, much like how people might group themselves by accent or dialect at a large gathering. The first major split separated the tumors into two broad categories: those that carry a specific genetic fusion, where two genes have fused together to create a new, powerful driver of cancer, and those that do not. This division matched the known split between fusion-positive and fusion-negative tumors, but the real surprise came when the researchers looked closer at the group without the fusion.

Within the fusion-negative group, which was previously thought to be a single, uniform type of tumor, the data revealed a complex landscape of distinct subgroups. One large, homogeneous group behaved exactly as expected, showing the typical features of the embryonal muscle tumors and responding to treatment in a predictable way. However, the other half of this group was a patchwork of different biological realities. One small cluster contained tumors with a specific mutation in a gene called MYOD1, which had been seen before but was now clearly defined as its own distinct category. Another group was particularly striking: these tumors looked like the aggressive, fusion-positive type under the microscope, yet they lacked the fusion gene entirely. Instead, these tumors, which the researchers called the AFN group, carried amplifications of genes in the MYC family, a set of genes known to drive rapid cell growth. This group proved that a tumor can be biologically aggressive and look like the high-risk type without having the specific fusion gene that usually defines it.

The researchers also identified a group of tumors that looked like the common embryonal type but were biologically different. These tumors, found in younger children, had fewer mutations in the pathways that usually drive cancer growth and showed a higher frequency of a specific gene amplification called MDM2. Perhaps most importantly, they found a group of samples that did not fit the mold of rhabdomyosarcoma at all. These samples turned out to be a mix of other rare cancers or tumors that were heavily contaminated with normal, healthy cells, making them difficult to classify. By separating these out, the researchers clarified that what was once thought to be a single, messy category was actually a collection of different diseases that had been lumped together.

The study also looked at how these new groups related to patient survival. The results showed that the different subgroups had very different stories to tell. The group with the MYOD1 mutation and the group with the fusion-negative but aggressive features both had poorer outcomes compared to the standard group. In contrast, the newly defined group of younger children with the specific genetic profile of the FN1/E group did not show a difference in survival compared to the standard group, suggesting that current treatments might be working well for them despite their unique biology. The researchers noted that the group with the fusion-positive tumors also showed a trend where one specific subtype had slightly worse outcomes than the other, reinforcing the idea that even within the known types, there is room for finer distinction.

This work does not immediately change how doctors treat patients in the clinic, but it provides a much clearer map of the territory. By using DNA methylation as a guide, the researchers have shown that rhabdomyosarcoma is not a single disease but a collection of distinct entities. They ruled out the idea that the aggressive-looking tumors without the fusion gene were simply misdiagnosed versions of the common type; instead, they are a unique biological entity driven by different genetic forces. They also demonstrated that the old visual classification system, while useful, is not precise enough to capture the full picture of these tumors. The findings suggest that in the future, doctors may be able to use these chemical fingerprints to sort children into more accurate groups, ensuring that those with the most aggressive forms of the disease receive the most intensive care, while those with less aggressive forms are spared unnecessary toxicity. The study confirms that looking deeper into the molecular instructions of a tumor can reveal truths that the naked eye cannot see, offering a path toward more personalized and effective care for children with this challenging disease.